TAF1

Summary

TAF1 (TATA-box binding protein associated factor 1, HGNC:11535) is a protein-coding gene on chromosome Xq13.1, encoding Transcription initiation factor TFIID subunit 1 (P21675). The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription. It is a selective cancer dependency (DepMap: 70.9% of cell lines).

Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is the basal transcription factor TFIID, which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes the largest subunit of TFIID. This subunit binds to core promoter sequences encompassing the transcription start site. It also binds to activators and other transcriptional regulators, and these interactions affect the rate of transcription initiation. This subunit contains two independent protein kinase domains at the N- and C-terminals, but also possesses acetyltransferase activity and can act as a ubiquitin-activating/conjugating enzyme. Mutations in this gene result in Dystonia 3, torsion, X-linked, a dystonia-parkinsonism disorder. Alternative splicing of this gene results in multiple transcript variants. This gene is part of a complex transcription unit (TAF1/DYT3), wherein some transcript variants share exons with TAF1 as well as additional downstream DYT3 exons.

Source: NCBI Gene 6872 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability, X-linked, syndromic 33 (Definitive, GenCC) — +2 more curated relationships
• Clinical variants (ClinVar): 972 total — 10 pathogenic, 23 likely-pathogenic
• Phenotypes (HPO): 113
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 70.9% of screened cell lines
• Transcription factor: yes — 44 downstream targets (CollecTRI)
• MANE Select transcript: NM_004606

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11535
Approved symbol	TAF1
Name	TATA-box binding protein associated factor 1
Location	Xq13.1
Locus type	gene with protein product
Status	Approved
Aliases	NSCL2, TAFII250, KAT4, DYT3/TAF1
Ensembl gene	ENSG00000147133
Ensembl biotype	protein_coding
OMIM	313650
Entrez	6872

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 11 nonsense_mediated_decay, 9 protein_coding, 7 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000276072, ENST00000373775, ENST00000373790, ENST00000423759, ENST00000437147, ENST00000461157, ENST00000461764, ENST00000462588, ENST00000463163, ENST00000467309, ENST00000468167, ENST00000472567, ENST00000474917, ENST00000478305, ENST00000482544, ENST00000483365, ENST00000483985, ENST00000485087, ENST00000492404, ENST00000682124, ENST00000683202, ENST00000683352, ENST00000683358, ENST00000683668, ENST00000683715, ENST00000683782, ENST00000683954, ENST00000715246, ENST00000945393

RefSeq mRNA: 3 — MANE Select: NM_004606 NM_001286074, NM_004606, NM_138923

CCDS: CCDS14412, CCDS35325

Canonical transcript exons

ENST00000423759 — 38 exons

Exon	Start	End
ENSE00000978923	71423117	71423239
ENSE00001592652	71401528	71401739
ENSE00001598091	71421309	71421376
ENSE00001606772	71382761	71382868
ENSE00001610045	71378235	71378453
ENSE00001615535	71376950	71377191
ENSE00001621948	71382991	71383164
ENSE00001652592	71397253	71397466
ENSE00001657433	71377603	71377821
ENSE00001663592	71392875	71392994
ENSE00001671320	71378824	71379031
ENSE00001684911	71387261	71387461
ENSE00001687499	71394067	71394245
ENSE00001693606	71367499	71367613
ENSE00001710784	71407574	71407672
ENSE00001716532	71407974	71408151
ENSE00001728655	71382536	71382663
ENSE00001748084	71381743	71381919
ENSE00001762617	71389585	71389665
ENSE00001762844	71375167	71375286
ENSE00001765081	71393301	71393476
ENSE00001781380	71392569	71392718
ENSE00001788701	71384945	71385049
ENSE00001801775	71383962	71384135
ENSE00001801856	71398572	71398737
ENSE00001806491	71368054	71368170
ENSE00001942720	71463824	71466005
ENSE00003518660	71388237	71388378
ENSE00003523014	71423974	71424066
ENSE00003549981	71424154	71424238
ENSE00003576755	71460626	71460803
ENSE00003598018	71454170	71454237
ENSE00003631125	71454741	71454857
ENSE00003648270	71388738	71388868
ENSE00003655608	71458241	71458366
ENSE00003692594	71459552	71459708
ENSE00003785247	71406638	71406746
ENSE00004026294	71366357	71366494

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 97.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.1347 / max 588.4982, expressed in 1801 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196684	18.5075	1795
196683	1.0177	627
196682	0.5020	232
196685	0.1075	52

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	97.11	gold quality
calcaneal tendon	UBERON:0003701	93.60	gold quality
tendon	UBERON:0000043	91.55	gold quality
colonic epithelium	UBERON:0000397	91.26	gold quality
urethra	UBERON:0000057	90.64	gold quality
tonsil	UBERON:0002372	90.24	gold quality
left ovary	UBERON:0002119	90.13	gold quality
mammary duct	UBERON:0001765	90.02	gold quality
pericardium	UBERON:0002407	89.90	gold quality
corpus callosum	UBERON:0002336	89.84	gold quality
body of uterus	UBERON:0009853	89.69	gold quality
right coronary artery	UBERON:0001625	89.47	gold quality
medial globus pallidus	UBERON:0002477	89.20	gold quality
right ovary	UBERON:0002118	89.13	gold quality
adrenal tissue	UBERON:0018303	89.10	gold quality
ectocervix	UBERON:0012249	89.01	gold quality
stromal cell of endometrium	CL:0002255	88.98	gold quality
globus pallidus	UBERON:0001875	88.96	gold quality
cardia of stomach	UBERON:0001162	88.95	gold quality
ovary	UBERON:0000992	88.91	gold quality
ventricular zone	UBERON:0003053	88.89	gold quality
endocervix	UBERON:0000458	88.88	gold quality
mucosa of stomach	UBERON:0001199	88.80	gold quality
popliteal artery	UBERON:0002250	88.75	gold quality
tibial artery	UBERON:0007610	88.74	gold quality
left uterine tube	UBERON:0001303	88.58	gold quality
seminal vesicle	UBERON:0000998	88.52	gold quality
descending thoracic aorta	UBERON:0002345	88.42	gold quality
aorta	UBERON:0000947	88.39	gold quality
tendon of biceps brachii	UBERON:0008188	88.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.21

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

44 targets.

Target	Regulation
AR	Activation
BAX	Repression
CCNA2	Activation
CCND1	Activation
CD74
CDKN1A	Activation
CDKN1B	Unknown
CIITA
CNTN2
DNM1L
DRD2	Repression
EGFR	Unknown
ELP3
ETS2
FLOT2
FOS
GTF2A1
HAT1
HLA-A	Unknown
HMOX1
HPSE2
HSPA5
IGFBP1
IGFBP7
KAT2A
KAT2B
LGALS7B	Repression
LRIG2	Unknown
MDM2	Repression
MYB	Unknown

Upstream regulators (CollecTRI, top): AR, ATF1, TBP

miRNA regulators (miRDB)

99 targeting TAF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 70.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• polymorphism of TAF1 gene does not influence the risk of myocardial infarction. (PMID:11871391)
• Evidence that TAF-TATA box-binding protein interactions are required for activated transcription in mammalian cells. (PMID:11909971)
• TAF1 may be involved in the coordinate expression of Pol I- and Pol II-transcribed genes required for protein biosynthesis and cell cycle progression. (PMID:12498690)
• TAFI polymorphisms investigated exerted no thrombogenic influence in pediatric oncology patients. (PMID:14719174)
• TAF1 induces G1 progression in a p53-dependent manner. It interacts with and phosphorylates p53 at Thr-55 in vivo. (PMID:15053879)
• hsTAF1 derepression of transcription requires the leucine zipper domain of c-Jun to bind to the N terminus of hsTAF1 (PMID:15087451)
• TAF1-dependent histone acetylation facilitates transcription factor binding to the Sp1 sites, thereby activating cyclin D1 transcription and ultimately G(1)-to-S-phase progression (PMID:15870300)
• DYT3 is the gene responsible for X-linked recessive dystonia-parkinsonism. (PMID:16366515)
• linkage disequilibrium observed in an African population enabled us to identify the 1583T>A SNP located in 3’UTR. (PMID:16705091)
• Downregulates E3 ubiquitin ligase Mdm2 auto-ubiquitylation, leading to Mdm2 stabilization, and promotes p53-Mdm2 association. (PMID:17237821)
• Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism (PMID:17273961)
• possible sites in hUBF HMG box 5 that may interact with the first bromodomain of TAF1 were proposed (PMID:17505112)
• Thirty-eight exons code for TAF1. Five downstream exons of yet unknown function can either form transcripts with TAF1 exons or be transcribed independently. Splice variants can include d plus at least 12 TAF1 exons. (PMID:17952504)
• CK2 is tightly associated with TAFII250 and is the principal activity responsible for TAFII250-mediated phosphorylation of Mdm2. (PMID:18548200)
• interacts with human papillomavirus 16 E2 protein. (PMID:18580066)
• Results indicate that increased TAF1 expression is associated with progression of human prostate cancers to the lethal castration-resistant state. (PMID:20181722)
• 285 patients with autosomal -dominant ataxia were examined, and abnormal or borderline expansions of CAG/CAA within TBP were found. (PMID:20587494)
• TAF7, until now considered only a TFIID component and regulator of TAF1-dependent transcription, also regulates TAF1-independent transcription (PMID:20937824)
• In the Brazilian population, genetic variations in both uPA and TAFI were not relevant to endometriosis and/or infertility. (PMID:21819230)
• analysis of phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7 (PMID:22711989)
• Although d3-d4 also affect genes potentially related to neurodegenerative processes, their physiologic role as splice variants of TAF1 awaits further exploration (PMID:23184149)
• This study demonistrated that frequencies of polymorphic genotype and allele of TAF1 gene were not different in patients than in control group and that they were not significant for cerebral venous thrombosis. (PMID:23264082)
• Lower efficiency of microRNA synthesis directed by TATA box or NF-kappaappaB is a consequence of frequent transcription initiations that lead to RNA polymerase II crowding at pause sites and premature termination. (PMID:23831825)
• As cellular ATP levels recover, TAF1 is able to phosphorylate p53 on Thr55, which leads to dissociation of p53 from the p21 promoter. (PMID:24289924)
• the surface of the TAF1-TAF7 complex contains two prominent conserved surface pockets, one of which binds selectively to an inhibitory trimethylated histone H3 (PMID:24927529)
• are necessary and sufficient to overcome the barrier of species specificity for human rDNA transcription in mouse cells (PMID:24928901)
• TAF1 winged helix domain has intrinsic DNA-binding activity, which depends on characteristic residues that are commonly used by winged helix fold proteins for interacting with DNA. (PMID:25412659)
• The bromodomains of BRD9, CECR2, and the second bromodomain of TAF1 recognize the longer butyryl mark on histones. In addition, the TAF1 second bromodomain is capable of binding crotonyl marks. (PMID:26365797)
• TAF1 variants are associated with dysmorphic features, intellectual disability, and neurological manifestations. (PMID:26637982)
• N-TAF1 expression is impaired in X-linked dystonia-parkinsonism. (PMID:26769797)
• The results converge on TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism, and provide evidence of altered expression of a canonical gene in this disease. Furthermore, this study illustrates a link between the previously described genetic alterations and TAF1 dysfunction at the transcriptome level. (PMID:26879577)
• TAF1 and TAF1L genes harbored not only somatic mutations but also mutational ITH. (PMID:27571988)
• These data directly link sequence variation within the XDP-specific SVA sequence to phenotypic variability in clinical disease manifestation and provide insight into potential mechanisms by which this intronic retroelement may induce transcriptional interference in TAF1 expression. (PMID:29229810)
• present a case study where a combination of experimental techniques and computational simulations was used to comprehensively characterize the binding and structure-affinity relationships for a series of Bromosporine-based bivalent bromodomain ligands with a bivalent protein, Transcription Initiation Factor TFIID subunit 1 (TAF1). (PMID:29558110)
• Our findings highlight the regulatory networks among TFs, lncRNAs, miRNAs, and mRNAs in hepatocellular carcinoma (HCC). Several key molecules, such as hsa-miR-195, lncRNA MALAT1 and TFs TAF1 and HNF4alpha, may contribute to the progression of HCC. (PMID:30249878)
• Liver fibrosis caused by hepatitis C virus results in altered hepatic expression of TAF1. (PMID:30317608)
• Repeat number showed significant inverse correlations with age-at-onset and with TAF1 expression and a positive correlation with parkinsonism disease severity and cognitive dysfunction. (PMID:30973967)
• Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma. (PMID:31283007)
• These findings reveal a role of TAF1 in leukemogenesis and identify TAF1 as a potential therapeutic target for AML1-ETO -expressing leukemia. (PMID:31664040)
• The Thr325Ile polymorphism, but no Ala147Thr polymorphism in TAF1 gene is associated with ST acute myocardial infarction. (PMID:31781299)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	taf1	ENSDARG00000035330
mus_musculus	Taf1	ENSMUSG00000031314
rattus_norvegicus	Taf1	ENSRNOG00000002565
drosophila_melanogaster	Taf1	FBGN0010355
caenorhabditis_elegans	taf-1	WBGENE00006382

Paralogs (1): TAF1L (ENSG00000122728)

Protein

Protein identifiers

Transcription initiation factor TFIID subunit 1 — P21675 (reviewed: P21675)

Alternative names: Cell cycle gene 1 protein, TBP-associated factor 250 kDa, Transcription initiation factor TFIID 250 kDa subunit

All UniProt accessions (16): P21675, A0A804HHS0, A0A804HIC2, A0A804HIY8, A0A804HJ34, A0A804HJ48, A0A804HJE0, A0A804HJT5, A0A804HK00, A0A804HK58, A0A804HLH3, A0AA75HR15, H0Y8N6, H0Y9L7, H7BY98, H7C2K9

UniProt curated annotations — full annotation on UniProt →

Function. The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription. TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13. TAF1 is the largest component and core scaffold of the TFIID complex, involved in nucleating complex assembly. TAF1 forms a promoter DNA binding subcomplex of TFIID, together with TAF7 and TAF2. Contains novel N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or transphosphorylate other transcription factors. Phosphorylates TP53 on ‘Thr-55’ which leads to MDM2-mediated degradation of TP53. Phosphorylates GTF2A1 and GTF2F1 on Ser residues. Possesses DNA-binding activity. Essential for progression of the G1 phase of the cell cycle. Exhibits histone acetyltransferase activity towards histones H3 and H4.

Subunit / interactions. Component of the TFIID basal transcription factor complex, composed of TATA-box-binding protein TBP, and a number of TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13. Interacts with TAF7; the interaction is direct. TAF1, when part of the TFIID complex, interacts with C-terminus of TP53. Part of a TFIID-containing RNA polymerase II pre-initiation complex that is composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13. Component of some MLL1/MLL complex, at least composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the facultative components BACC1, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, KAT8/MOF, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. RB1 interacts with the N-terminal domain of TAF1. Interacts with ASF1A and ASF1B. Interacts (via bromo domains) with acetylated lysine residues on the N-terminus of histone H1.4, H2A, H2B, H3 and H4 (in vitro). (Microbial infection) Interacts with SV40 Large T antigen. (Microbial infection) Interacts with herpes simplex virus 1 ICP4.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylated by casein kinase II in vitro.

Disease relevance. Dystonia 3, torsion, X-linked (DYT3) [MIM:314250] An X-linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. It has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease. The disease is caused by variants affecting the gene represented in this entry. Intellectual developmental disorder, X-linked, syndromic 33 (MRXS33) [MIM:300966] A syndrome characterized by intellectual deficit, delayed psychomotor development, delayed speech and language, and characteristic facial features. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Autophosphorylates on Ser residues. Inhibited by retinoblastoma tumor suppressor protein, RB1. Binding to TAF7 or CIITA inhibits the histone acetyltransferase activity.

Domain organisation. The Bromo domain mediates interaction with histones that have acetylated lysine residues at specific positions. The second domain also recognizes and binds histones that are butyrylated and crotonylated.

Miscellaneous. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. Includes a downstream (d) exon and is preferentially expressed in brain. May play a role in the regulation of genes involved in dopamine processing and transport. May be produced at very low levels due to a premature stop CC codon in the mRNA, leading to nonsense-mediated mRNA decay. Only detected in brain, highest expression in the caudate nucleus.

Similarity. Belongs to the TAF1 family.

Isoforms (15)

UniProt ID	Names	Canonical?
P21675-2	2	yes
P21675-1	1
P21675-13	13
P21675-14	14
P21675-15	15
P21675-16	16
P21675-17	N-TAF1, TA14-391
P21675-18	2a
P21675-19	2c
P21675-20	2d
P21675-21	2e
P21675-22	2g
P21675-23	2h
P21675-24	2i
P21675-25	4

RefSeq proteins (3): NP_001273003, NP_004597, NP_620278 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001487	Bromodomain	Domain
IPR009067	TAF_II_230-bd	Domain
IPR011177	TAF1_animal	Family
IPR018359	Bromodomain_CS	Conserved_site
IPR022591	TAF1_HAT_dom	Domain
IPR036427	Bromodomain-like_sf	Homologous_superfamily
IPR036741	TAFII-230_TBP-bd_sf	Homologous_superfamily
IPR040240	TAF1	Family
IPR041670	Znf-CCHC_6	Domain

Pfam: PF00439, PF09247, PF12157, PF15288

Enzyme classification (BRENDA):

• EC 2.3.1.48 — histone acetyltransferase (BRENDA: 41 organisms, 681 substrates, 1134 inhibitors, 140 Km, 96 kcat entries)

Substrate kinetics (BRENDA)

27 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ACETYL-COA	0.0002–0.046	51
HISTONE H3	0.007–2.09	23
HISTONE H4	—	11
HISTONE H4 PEPTIDE	0.0208–0.197	7
HISTONE	0.075–1.4	6
HISTONE H3 TAIL PEPTIDE	0.044–0.112	4
PICCOLONUA4 PEPTIDE	0.135–0.372	4
3-AZIDOPROPIONYL-COA	0.0002–0.0086	3
4-PENTYNOYL-COA	0.0009–0.0859	3
SPERMIDINE	0.18–0.27	3
5-HEXYNOYL-COA	0.0006–0.0117	2
6-HEPTYNOYL-COA	0.0003–0.0237	2
HISTONE H3-PEPTIDE	0.05–0.49	2
PROTEIN P53	1.28–4.63	2
3-AZIDOPROPANOYL-COA	0.0103	1

Catalyzed reactions (Rhea), 3 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-lysyl-[protein] + acetyl-CoA = N(6)-acetyl-L-lysyl-[protein] + CoA + H(+) (RHEA:45948)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (166 total): helix 41, strand 31, sequence variant 15, splice variant 14, mutagenesis site 14, modified residue 13, region of interest 11, compositionally biased region 11, turn 7, domain 4, cross-link 2, chain 1, short sequence motif 1, DNA-binding region 1

Structure

Experimental structures (PDB)

64 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
5I29	X-RAY DIFFRACTION	1.21
7LB1	X-RAY DIFFRACTION	1.35
4YYM	X-RAY DIFFRACTION	1.5
5I1Q	X-RAY DIFFRACTION	1.5
7K27	X-RAY DIFFRACTION	1.5
7JJG	X-RAY DIFFRACTION	1.6
7K03	X-RAY DIFFRACTION	1.6
7T36	X-RAY DIFFRACTION	1.65
7JSP	X-RAY DIFFRACTION	1.7
7K3O	X-RAY DIFFRACTION	1.7
7K42	X-RAY DIFFRACTION	1.7
7LB2	X-RAY DIFFRACTION	1.7
5MG2	X-RAY DIFFRACTION	1.75
4YYN	X-RAY DIFFRACTION	1.85
7K6F	X-RAY DIFFRACTION	1.86
3UV4	X-RAY DIFFRACTION	1.89
7T2I	X-RAY DIFFRACTION	1.89
7LB3	X-RAY DIFFRACTION	1.9
7N42	X-RAY DIFFRACTION	1.9
3UV5	X-RAY DIFFRACTION	2.03
7JTC	X-RAY DIFFRACTION	2.05
1EQF	X-RAY DIFFRACTION	2.1
7JJH	X-RAY DIFFRACTION	2.1
6BQD	X-RAY DIFFRACTION	2.14
7P4S	X-RAY DIFFRACTION	2.17
6FIC	X-RAY DIFFRACTION	2.18
7K0D	X-RAY DIFFRACTION	2.2
4RGW	X-RAY DIFFRACTION	2.3
7LB0	X-RAY DIFFRACTION	2.33
7K1P	X-RAY DIFFRACTION	2.45

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P21675-F1	62.62	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (15): 1718, 1721, 1723, 1721, 137, 328, 565, 1690, 1693, 1799, 1802, 1820, 1847, 570, 583

Mutagenesis-validated functional residues (14):

Position	Phenotype
137	no decrease in kinase activity.
145	reduces kinase activity; when associated with a-147; a-149; a-150; a-152 and a-154.
147	reduces kinase activity; when associated with a-145; a-149; a-150; a-152 and a-154.
149	reduces kinase activity; when associated with a-145; a-147; a-150; a-152 and a-154.
150	reduces kinase activity; when associated with a-145; a-147; a-149; a-152 and a-154.
152	reduces kinase activity; when associated with a-145; a-147; a-149; a-150 and a-154.
154	reduces kinase activity; when associated with a-145; a-147; a-149; a-150 and a-152.
326	reduces kinase activity; when associated with a-328; a-329; a-330 and a-331.
328	reduces kinase activity; when associated with a-326; a-329; a-330 and a-331.
329	reduces kinase activity; when associated with a-326; a-328; a-330 and a-331.
330	reduces kinase activity; when associated with a-326; a-328; a-329 and a-331.
331	reduces kinase activity; when associated with a-326; a-328; a-329 and a-330.
742	25% decrease in histone acetylation.
848–850	dramatic decrease in histone acetylation.

Function

Pathways and Gene Ontology

Reactome pathways

20 pathways

ID	Pathway
R-HSA-167161	HIV Transcription Initiation
R-HSA-167162	RNA Polymerase II HIV Promoter Escape
R-HSA-167172	Transcription of the HIV genome
R-HSA-674695	RNA Polymerase II Pre-transcription Events
R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation
R-HSA-73776	RNA Polymerase II Promoter Escape
R-HSA-73779	RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-75953	RNA Polymerase II Transcription Initiation
R-HSA-76042	RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-162587	HIV Life Cycle
R-HSA-162599	Late Phase of HIV Life Cycle
R-HSA-162906	HIV Infection
R-HSA-1643685	Disease
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-5633007	Regulation of TP53 Activity
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9824446	Viral Infection Pathways

MSigDB gene sets: 500 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, WANG_CLIM2_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GRUETZMANN_PANCREATIC_CANCER_DN, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_CELLULAR_RESPONSE_TO_UV, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, MODULE_45, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY

GO Biological Process (27): negative regulation of transcription by RNA polymerase II (GO:0000122), protein polyubiquitination (GO:0000209), transcription initiation at RNA polymerase I promoter (GO:0006361), transcription by RNA polymerase II (GO:0006366), transcription initiation at RNA polymerase II promoter (GO:0006367), ubiquitin-dependent protein catabolic process (GO:0006511), DNA damage response (GO:0006974), negative regulation of gene expression (GO:0010629), midbrain development (GO:0030901), positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436), cellular response to UV (GO:0034644), mRNA transcription by RNA polymerase II (GO:0042789), positive regulation of transcription by RNA polymerase II (GO:0045944), protein autophosphorylation (GO:0046777), protein stabilization (GO:0050821), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261), cellular response to ATP (GO:0071318), positive regulation of androgen receptor signaling pathway (GO:0160207), regulation of signal transduction by p53 class mediator (GO:1901796), negative regulation of signal transduction by p53 class mediator (GO:1901797), regulation of cell cycle G1/S phase transition (GO:1902806), negative regulation of protein autoubiquitination (GO:1905524), negative regulation of ubiquitin-dependent protein catabolic process (GO:2000059), chromatin organization (GO:0006325), chromatin remodeling (GO:0006338), DNA-templated transcription initiation (GO:0006352)

GO Molecular Function (27): RNA polymerase II core promoter sequence-specific DNA binding (GO:0000979), RNA polymerase II general transcription initiation factor binding (GO:0001091), RNA polymerase I general transcription initiation factor activity (GO:0001181), p53 binding (GO:0002039), histone acetyltransferase activity (GO:0004402), protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), RNA polymerase II general transcription initiation factor activity (GO:0016251), kinase activity (GO:0016301), nuclear receptor binding (GO:0016922), TBP-class protein binding (GO:0017025), sequence-specific DNA binding (GO:0043565), protein heterodimerization activity (GO:0046982), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), ubiquitin conjugating enzyme activity (GO:0061631), protein serine kinase activity (GO:0106310), histone H4K16ac reader activity (GO:0140046), transcription regulator inhibitor activity (GO:0140416), nucleotide binding (GO:0000166), DNA binding (GO:0003677), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), histone H3K27me3 reader activity (GO:0061628), protein-lysine-acetyltransferase activity (GO:0061733), histone reader activity (GO:0140566)

GO Cellular Component (7): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), transcription factor TFIID complex (GO:0005669), MLL1 complex (GO:0071339), nucleolus (GO:0005730)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
RNA Polymerase II Transcription	4
Transcription of the HIV genome	2
RNA Polymerase II Transcription Initiation And Promoter Clearance	2
Late Phase of HIV Life Cycle	1
Regulation of TP53 Activity	1
HIV Infection	1
HIV Life Cycle	1
Viral Infection Pathways	1
Generic Transcription Pathway	1
Transcriptional Regulation by TP53	1
Disease	1
Gene expression (Transcription)	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	5
regulation of transcription by RNA polymerase II	2
protein ubiquitination	2
DNA-templated transcription initiation	2
transcription by RNA polymerase I	2
regulation of gene expression	2
transcription initiation at RNA polymerase II promoter	2
general transcription initiation factor binding	2
general transcription initiation factor activity	2
protein kinase activity	2
cellular anatomical structure	2
nuclear lumen	2
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
modification-dependent protein catabolic process	1
cellular response to stress	1
gene expression	1
negative regulation of macromolecule biosynthetic process	1
brain development	1
anatomical structure development	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
positive regulation of proteasomal protein catabolic process	1
positive regulation of ubiquitin-dependent protein catabolic process	1
response to UV	1
cellular response to light stimulus	1
mRNA transcription	1
positive regulation of DNA-templated transcription	1
protein phosphorylation	1
regulation of protein stability	1
transcription preinitiation complex assembly	1
positive regulation of transcription by RNA polymerase II	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
response to ATP	1
cellular response to nitrogen compound	1
cellular response to oxygen-containing compound	1
androgen receptor signaling pathway	1
positive regulation of intracellular steroid hormone receptor signaling pathway	1
regulation of androgen receptor signaling pathway	1

Protein interactions and networks

STRING

2966 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAF1	TBP	P20226	999
TAF1	TAF2	Q6P1X5	996
TAF1	TAF7	Q15545	995
TAF1	H4C7	Q99525	965
TAF1	H4C16	P02304	964
TAF1	TAF6	P49848	951
TAF1	TAF10	Q12962	950
TAF1	TAF12	Q16514	946
TAF1	TAF4	O00268	942
TAF1	TAF5	Q15542	938
TAF1	GTF2B	Q00403	934
TAF1	TAF11	Q15544	901
TAF1	TP53	P04637	886
TAF1	TAF9	Q16594	872
TAF1	POLR2A	P24928	869

IntAct

113 interactions, top by confidence:

A	B	Type	Score
TBP	TAF1	psi-mi:“MI:0914”(association)	0.890
TAF1	TBP	psi-mi:“MI:0915”(physical association)	0.890
TBP	TAF1	psi-mi:“MI:0915”(physical association)	0.890
TBP	TAF1	psi-mi:“MI:0407”(direct interaction)	0.890
TAF12	TAF4	psi-mi:“MI:0914”(association)	0.760
TBP	TAF4	psi-mi:“MI:0914”(association)	0.730
TAF10	TAF4	psi-mi:“MI:0914”(association)	0.650
TAF10	TAF4	psi-mi:“MI:0915”(physical association)	0.650
CA10	WDHD1	psi-mi:“MI:0914”(association)	0.640
RPL10A	RRP8	psi-mi:“MI:0914”(association)	0.640
TAF1		psi-mi:“MI:0915”(physical association)	0.590
	TAF1	psi-mi:“MI:0915”(physical association)	0.590
TAF8	TAF4	psi-mi:“MI:0914”(association)	0.530
SPATA25	TAF4	psi-mi:“MI:0914”(association)	0.530
TAF7L	TAF4	psi-mi:“MI:0914”(association)	0.530
TFDP3	E2F3	psi-mi:“MI:0914”(association)	0.530

BioGRID (366): TAF1 (Two-hybrid), TAF1 (Reconstituted Complex), TAF1 (Affinity Capture-RNA), TAF1 (Affinity Capture-RNA), TAF1 (Protein-peptide), HIST1H1A (Biochemical Activity), PAX3 (Biochemical Activity), TAF1 (Affinity Capture-MS), TAF1 (Affinity Capture-MS), TAF1 (Co-fractionation), TAF1 (Co-fractionation), TAF3 (Co-fractionation), TAF5 (Co-fractionation), TAF1 (Synthetic Growth Defect), TAF1 (Affinity Capture-Western)

ESM2 similar proteins: A0JNI5, A2AQ19, D3ZTQ1, O43290, O43395, P21675, P35269, P49140, Q02614, Q12872, Q13435, Q2KIA6, Q2KIT1, Q3THK3, Q3TIV5, Q3U155, Q3UJB0, Q3USH5, Q53F19, Q5EA53, Q5HZB6, Q5R5F1, Q5R5J3, Q5RAD5, Q5U3K5, Q5XIW8, Q5ZIH9, Q5ZJ85, Q5ZM19, Q60544, Q6AY96, Q6PII3, Q6U6G5, Q75QI0, Q80UV9, Q8BVA4, Q8BZR9, Q8CFC7, Q8N2M8, Q8WU90

Diamond homologs: A0A0R4IXF6, A0A7U2QYM2, A2AHJ4, A2AUY4, A2BIL7, B2RRD7, B7ZS37, D4A7T3, E9Q2Z1, F1QW93, F1R5H6, F7DRV9, G5E8P1, O15164, O60885, O74350, O88379, O88665, O95696, P13709, P21675, P25440, P35817, P51123, P53236, P54816, P55201, P87152, Q02206, Q03330, Q07442, Q08D75, Q09948, Q12830, Q15059, Q1LUC3, Q23590, Q32S26, Q338B9, Q4R8Y1

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
TAF1	“up-regulates activity”	GTF2A1	phosphorylation
TAF1	up-regulates	GTF2A1	phosphorylation
TAF1	down-regulates	TP53	phosphorylation
TAF1	“form complex”	TFIID	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 85 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HIV Transcription Initiation	12	53.8×	1e-16
RNA Polymerase II HIV Promoter Escape	12	53.8×	1e-16
RNA Polymerase II Promoter Escape	12	53.8×	1e-16
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening	12	53.8×	1e-16
RNA Polymerase II Transcription Initiation	12	53.8×	1e-16
RNA Polymerase II Transcription Initiation And Promoter Clearance	12	53.8×	1e-16
Transcription of the HIV genome	13	43.3×	1e-16
Late Phase of HIV Life Cycle	12	38.8×	6e-15

GO biological processes:

GO term	Partners	Fold	FDR
DNA-templated transcription initiation	5	65.0×	9e-07
transcription initiation at RNA polymerase II promoter	12	62.4×	2e-16
RNA polymerase II preinitiation complex assembly	12	45.3×	4e-15
positive regulation of transcription initiation by RNA polymerase II	12	45.3×	4e-15
mRNA transcription by RNA polymerase II	8	36.7×	5e-09
regulation of DNA repair	6	23.0×	2e-05
transcription by RNA polymerase II	9	8.8×	5e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

972 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	10
Likely pathogenic	23
Uncertain significance	392
Likely benign	197
Benign	77

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1344721	NM_004606.5(TAF1):c.1454T>A (p.Ile485Asn)	Pathogenic
1344726	NM_004606.5(TAF1):c.4295G>A (p.Arg1432His)	Pathogenic
1683951	NM_004606.5(TAF1):c.3095C>T (p.Thr1032Ile)	Pathogenic
219114	NM_004606.5(TAF1):c.3950T>C (p.Ile1317Thr)	Pathogenic
219118	NM_004606.5(TAF1):c.2866G>C (p.Asp956His)	Pathogenic
2430292	NM_004606.5(TAF1):c.1943_1947+1del	Pathogenic
4077400	NM_004606.5(TAF1):c.2120G>T (p.Arg707Leu)	Pathogenic
599303	NM_004606.5(TAF1):c.3508C>T (p.Arg1170Cys)	Pathogenic
694247	NM_004606.5(TAF1):c.2975C>T (p.Thr992Ile)	Pathogenic
9862	NG_012771.2:g.79230_79231ins[AB191243.1:g.261508_264134]	Pathogenic
1028276	NM_004606.5(TAF1):c.2120G>A (p.Arg707Gln)	Likely pathogenic
1098389	NM_004606.5(TAF1):c.4276A>G (p.Met1426Val)	Likely pathogenic
1301994	NM_004606.5(TAF1):c.4748A>G (p.Tyr1583Cys)	Likely pathogenic
1309672	NM_004606.5(TAF1):c.2711A>G (p.Tyr904Cys)	Likely pathogenic
1334495	NM_004606.5(TAF1):c.4286A>C (p.Gln1429Pro)	Likely pathogenic
1344722	NM_004606.5(TAF1):c.2873C>T (p.Thr958Met)	Likely pathogenic
219115	NM_004606.5(TAF1):c.2359T>C (p.Cys787Arg)	Likely pathogenic
2229151	NM_004606.5(TAF1):c.2182dup (p.Thr728fs)	Likely pathogenic
2504010	NM_004606.5(TAF1):c.3407-1G>A	Likely pathogenic
2506487	NM_004606.5(TAF1):c.2414G>A (p.Arg805Gln)	Likely pathogenic
2573825	NM_004606.5(TAF1):c.3701G>A (p.Arg1234Gln)	Likely pathogenic
3342317	NM_004606.5(TAF1):c.4270C>T (p.Arg1424Trp)	Likely pathogenic
3381218	NM_004606.5(TAF1):c.2324G>T (p.Arg775Leu)	Likely pathogenic
372844	NM_004606.5(TAF1):c.2894C>T (p.Ser965Phe)	Likely pathogenic
419442	NM_004606.5(TAF1):c.4394A>G (p.His1465Arg)	Likely pathogenic
430463	NM_004606.5(TAF1):c.3973G>A (p.Val1325Ile)	Likely pathogenic
452882	NM_004606.5(TAF1):c.4316T>C (p.Leu1439Pro)	Likely pathogenic
545434	NM_004606.5(TAF1):c.4226C>T (p.Pro1409Leu)	Likely pathogenic
694242	NM_004606.5(TAF1):c.1520A>G (p.Asp507Gly)	Likely pathogenic
694248	NM_004606.5(TAF1):c.3700C>T (p.Arg1234Trp)	Likely pathogenic

SpliceAI

5841 predictions. Top by Δscore:

Variant	Effect	Δscore
X:71366409:G:GT	donor_gain	1.0000
X:71366478:A:T	donor_gain	1.0000
X:71368050:ATAG:A	acceptor_gain	1.0000
X:71368050:ATAGG:A	acceptor_gain	1.0000
X:71368052:AG:A	acceptor_gain	1.0000
X:71368053:GG:G	acceptor_gain	1.0000
X:71368053:GGGT:G	acceptor_gain	1.0000
X:71375164:TAGAT:T	acceptor_loss	1.0000
X:71375165:A:AG	acceptor_gain	1.0000
X:71375166:G:GG	acceptor_gain	1.0000
X:71375166:GA:G	acceptor_gain	1.0000
X:71375166:GATT:G	acceptor_gain	1.0000
X:71375166:GATTA:G	acceptor_gain	1.0000
X:71375282:TGGTG:T	donor_gain	1.0000
X:71375283:GGTGG:G	donor_gain	1.0000
X:71375284:GTG:G	donor_gain	1.0000
X:71375285:TG:T	donor_gain	1.0000
X:71375285:TGGTA:T	donor_loss	1.0000
X:71375286:GG:G	donor_gain	1.0000
X:71375287:G:GG	donor_gain	1.0000
X:71375288:T:A	donor_loss	1.0000
X:71376942:T:TA	acceptor_gain	1.0000
X:71376945:TGCA:T	acceptor_loss	1.0000
X:71376946:GCAG:G	acceptor_loss	1.0000
X:71376948:A:AG	acceptor_gain	1.0000
X:71376948:AGT:A	acceptor_gain	1.0000
X:71376949:G:GA	acceptor_gain	1.0000
X:71376949:GT:G	acceptor_gain	1.0000
X:71376949:GTG:G	acceptor_gain	1.0000
X:71376949:GTGT:G	acceptor_gain	1.0000

AlphaMissense

12607 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:71377654:T:A	W255R	1.000
X:71377654:T:C	W255R	1.000
X:71378325:T:A	W341R	1.000
X:71378325:T:C	W341R	1.000
X:71378327:G:C	W341C	1.000
X:71378327:G:T	W341C	1.000
X:71378349:T:A	W349R	1.000
X:71378349:T:C	W349R	1.000
X:71378902:T:A	W410R	1.000
X:71378902:T:C	W410R	1.000
X:71378903:G:C	W410S	1.000
X:71378904:G:C	W410C	1.000
X:71378904:G:T	W410C	1.000
X:71378977:G:C	G435R	1.000
X:71378978:G:A	G435D	1.000
X:71378980:T:A	W436R	1.000
X:71378980:T:C	W436R	1.000
X:71378981:G:C	W436S	1.000
X:71378982:G:C	W436C	1.000
X:71378982:G:T	W436C	1.000
X:71379002:G:T	R443M	1.000
X:71381782:C:T	S466F	1.000
X:71381787:T:C	F468L	1.000
X:71381788:T:C	F468S	1.000
X:71381789:T:A	F468L	1.000
X:71381789:T:G	F468L	1.000
X:71381823:T:A	W480R	1.000
X:71381823:T:C	W480R	1.000
X:71381825:G:C	W480C	1.000
X:71381825:G:T	W480C	1.000

dbSNP variants (sampled 300 via entrez): RS1000000679 (X:71473506 A>T), RS1000027414 (X:71391736 C>T), RS1000056100 (X:71380077 C>T), RS1000067656 (X:71400535 A>G), RS1000073081 (X:71529697 T>C), RS1000135678 (X:71382401 G>A,C,T), RS1000145684 (X:71376798 T>G), RS1000199026 (X:71412941 G>A), RS1000207469 (X:71446251 G>A), RS1000229919 (X:71439644 C>T), RS1000243806 (X:71430727 A>G), RS1000257789 (X:71498745 A>G), RS1000262614 (X:71492197 A>C), RS1000361391 (X:71367529 G>A,C), RS1000364002 (X:71431113 C>A)

Disease associations

OMIM: gene MIM:313650 | disease phenotypes: MIM:314250, MIM:300966, MIM:308350

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability, X-linked, syndromic 33	Definitive	X-linked
X-linked dystonia-parkinsonism	Strong	X-linked
X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome	Supportive	X-linked

Mondo (6): X-linked dystonia-parkinsonism (MONDO:0010747), intellectual disability, X-linked, syndromic 33 (MONDO:0010500), autism spectrum disorder (MONDO:0005258), intellectual disability (MONDO:0001071), genetic developmental and epileptic encephalopathy (MONDO:0100062), (MONDO:0018823)

Orphanet (4): X-linked dystonia-parkinsonism (Orphanet:53351), X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome (Orphanet:480907), NON RARE IN EUROPE: Autism (Orphanet:106), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

113 total (30 of 113 shown, HPO-id order):

HPO	Term
HP:0000218	High palate
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000276	Long face
HP:0000286	Epicanthus
HP:0000307	Pointed chin
HP:0000308	Microretrognathia
HP:0000316	Hypertelorism
HP:0000336	Prominent supraorbital ridges
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000389	Chronic otitis media
HP:0000391	Thickened helices
HP:0000400	Macrotia
HP:0000411	Protruding ear
HP:0000414	Bulbous nose
HP:0000437	Depressed nasal tip
HP:0000455	Broad nasal tip
HP:0000463	Anteverted nares
HP:0000470	Short neck
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000494	Downslanted palpebral fissures
HP:0000496	Abnormality of eye movement
HP:0000520	Proptosis
HP:0000527	Long eyelashes
HP:0000545	Myopia
HP:0000574	Thick eyebrow

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
C564048	Dystonia 3, Torsion, X-Linked (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3217390 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 2,955 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL4285417	CERALASERTIB	3	1,469
CHEMBL513909	BI-2536	2	895
CHEMBL4078100	AZD-5153	1	591

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — TAF1 family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
BAY-299	Inhibition	7.89	pIC50

Binding affinities (BindingDB)

591 measured of 597 human assays (597 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[(11S)-10-ethynyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	0.799 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-bromo-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	1 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-chloro-4-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	2 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-10-ethyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	2.08 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-7-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-7-fluoro-4-methyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
[1-[(11R)-10-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-4,6-dioxo-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazin-7-yl]boronic acid	EC50	3.05 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-10-(dimethylamino)-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.12 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
(3S)-2-[(11R)-10-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione	EC50	3.5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-7-methyl-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
5-hydroxy-1-[(11S)-10-(trifluoromethyl)-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.51 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-chloro-4-methyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.64 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-chloro-3-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.68 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4,10-dimethyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.78 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-8,9-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.84 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-7-(hydroxymethyl)-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.91 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-10-ethynyl-4-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	3.93 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-9-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-7-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-8-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-10-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4,7-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4-chloro-7-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4-chloro-8-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-10-cyclopropyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4.05 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11R)-10-bromo-4-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4.05 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4.28 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
5-hydroxy-1-[(11S)-10-methoxy-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	4.32 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-(4-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-5-hydroxy-3-propan-2-yl-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-9-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-7-bromo-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-3,10-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
5-hydroxy-1-[(11S)-10-methyl-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
7-chloro-1-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5.6 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
7-chloro-1-[(11R)-10-chloro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	5.9 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4-bromo-8-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	6 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-(6,13-difluoro-2-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaenyl)-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	6 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-10-ethyl-4-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	6.33 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-7-(hydroxymethyl)-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	6.45 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
[1-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-4,6-dioxo-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazin-7-yl]boronic acid	EC50	7.09 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
7-acetyl-1-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	7.19 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-(4-chloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	7.86 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-(2-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	8 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-2-fluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	8 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
dimethyl 1-[(1S)-1-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-4-oxo-3-phenylmethoxypyridine-2,5-dicarboxylate	EC50	8 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug
1-[(11S)-4,10-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2H-pyrido[2,1-f][1,2,4]triazine-4,6-dione	EC50	8 nM	US-10202379: Substituted polycyclic carbamoyl pyridone derivative prodrug

ChEMBL bioactivities

214 potent at pChembl≥5 of 235 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.70	Ki	0.1995	nM	CHEMBL4868363
9.40	Ki	0.3981	nM	CHEMBL4850335
9.10	Ki	0.7943	nM	CHEMBL4864027
9.00	Ki	1	nM	CHEMBL4873236
8.90	Ki	1.259	nM	CHEMBL4854161
8.52	IC50	3	nM	CHEMBL4062266
8.40	IC50	4	nM	CHEMBL4086958
8.40	IC50	4	nM	CHEMBL4072812
8.40	IC50	4	nM	CHEMBL4440829
8.22	IC50	6	nM	CHEMBL4091912
8.22	IC50	6	nM	CHEMBL4453202
8.22	IC50	6	nM	CHEMBL4441257
8.22	IC50	6	nM	CHEMBL4586175
8.15	IC50	7	nM	CHEMBL4092917
8.15	IC50	7	nM	CHEMBL4059651
8.15	IC50	7	nM	CHEMBL4566599
8.10	IC50	8	nM	CHEMBL4075478
8.10	IC50	8	nM	CHEMBL4086276
8.04	Kd	9.1	nM	CHEMBL4648912
8.03	Kd	9.3	nM	CHEMBL4086276
8.00	IC50	10	nM	CHEMBL4463538
8.00	IC50	10	nM	CHEMBL4455513
8.00	IC50	10	nM	CHEMBL4520419
7.96	IC50	11	nM	CHEMBL4086276
7.96	IC50	11	nM	CHEMBL4437997
7.89	IC50	13	nM	CHEMBL4077317
7.89	IC50	13	nM	CHEMBL4086276
7.89	IC50	13	nM	CHEMBL4459660
7.85	IC50	14	nM	CHEMBL4076067
7.82	IC50	15	nM	CHEMBL4104538
7.82	IC50	15	nM	CHEMBL4448723
7.80	IC50	16	nM	CHEMBL4589721
7.80	IC50	16	nM	CHEMBL4445482
7.80	IC50	16	nM	CHEMBL4513694
7.80	IC50	16	nM	CHEMBL4468549
7.80	IC50	16	nM	CHEMBL4459431
7.80	Kd	15.85	nM	CHEMBL4449894
7.78	Kd	16.61	nM	CHEMBL4086276
7.78	Kd	16.6	nM	CHEMBL3133807
7.77	IC50	17	nM	CHEMBL4081145
7.77	IC50	17	nM	CHEMBL4086276
7.77	IC50	17	nM	CHEMBL4483679
7.77	Kd	17	nM	CHEMBL3133807
7.72	IC50	19	nM	CHEMBL4065133
7.66	IC50	22	nM	CHEMBL4099171
7.64	IC50	23	nM	CHEMBL4463398
7.60	IC50	25	nM	CHEMBL4064164
7.58	IC50	26	nM	CHEMBL4448345
7.55	IC50	28	nM	CHEMBL4534244
7.51	IC50	31	nM	CHEMBL4534000

PubChem BioAssay actives

194 with measured affinity, of 389 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
8-[[1-(3-amino-2-fluoropropanoyl)piperidin-4-yl]amino]-5-(3,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-1,7-naphthyridin-2-one	1766145: Inhibition of human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	ki	0.0002	uM
8-[[1-(3-aminopropyl)piperidin-4-yl]amino]-5-(3,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-1,7-naphthyridin-2-one	1766145: Inhibition of human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	ki	0.0004	uM
8-[[1-(3-amino-2,2-difluoropropanoyl)piperidin-4-yl]amino]-5-(3,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-1,7-naphthyridin-2-one	1766145: Inhibition of human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	ki	0.0008	uM
8-[[1-(3-amino-2-fluoropropyl)piperidin-4-yl]amino]-5-(3,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-1,7-naphthyridin-2-one	1766145: Inhibition of human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	ki	0.0010	uM
8-[[1-(3-aminopropanoyl)piperidin-4-yl]amino]-5-(3,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-1,7-naphthyridin-2-one	1766145: Inhibition of human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	ki	0.0013	uM
6-(propylamino)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0030	uM
6-(4-methylpiperazin-1-yl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0040	uM
6-bromo-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0040	uM
6-but-3-enyl-4-[6-ethoxy-5-(morpholine-4-carbonyl)-3-pyridinyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0040	uM
6-but-3-enyl-4-[3-ethyl-7-(morpholine-4-carbonyl)benzimidazol-5-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0060	uM
6-but-3-enyl-4-[3-(difluoromethoxy)-5-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0060	uM
6-[methyl(2-pyrrolidin-1-ylethyl)amino]-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0060	uM
6-but-3-enyl-4-[4-chloro-3-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0060	uM
6-piperidin-1-yl-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0070	uM
6-(4-hydroxybutyl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0070	uM
6-but-3-enyl-4-[6-methoxy-5-(morpholine-4-carbonyl)-3-pyridinyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0070	uM
6-(3-hydroxypropyl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0080	uM
6-chloro-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0080	uM
N-[1-(1,1-dipyridin-2-ylethyl)-6-(1-methyl-7-oxo-6H-pyrrolo[2,3-c]pyridin-3-yl)indol-4-yl]ethanesulfonamide	1652268: Binding affinity to human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.0091	uM
6-but-3-enyl-4-[1-methyl-6-(morpholine-4-carbonyl)benzimidazol-4-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0100	uM
6-but-3-enyl-4-[1-methyl-7-(morpholine-4-carbonyl)benzimidazol-5-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0100	uM
6-but-3-enyl-4-[4-fluoro-3-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0100	uM
4-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	1512553: Displacement of biotinylated probe from human TAF1 bromodomain 2 (1522 to 1656 residues) expressed in Escherichia coli BL21 (DE3) by alphascreen assay	ic50	0.0100	uM
6-but-3-enyl-4-[3,4-difluoro-5-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0110	uM
5-hydroxy-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0130	uM
6-but-3-enyl-4-[6-methyl-5-(morpholine-4-carbonyl)-3-pyridinyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0130	uM
6-[4-(cyclopropylmethyl)piperazin-1-yl]-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0140	uM
3-(6-but-3-enyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-5-(morpholine-4-carbonyl)benzonitrile	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0150	uM
6-(4-methoxypiperidin-1-yl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0150	uM
N-[4-bromo-3-[(3S)-3-methylpyrrolidin-1-yl]sulfonylphenyl]-2-[(4S)-4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl]acetamide	1561912: Binding affinity to human partial length TAF1 bromodomain 2 (D1521 to D1656 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.0158	uM
6-but-3-enyl-4-[3-methyl-7-(morpholine-4-carbonyl)benzimidazol-5-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0160	uM
6-but-3-enyl-4-[7-(morpholine-4-carbonyl)-3H-benzimidazol-5-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0160	uM
6-but-3-enyl-4-[1-ethyl-7-(morpholine-4-carbonyl)benzimidazol-5-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0160	uM
6-but-3-enyl-4-[5-(morpholine-4-carbonyl)-3-pyridinyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0160	uM
4-[[(3R)-4-cyclopentyl-1,3-dimethyl-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide	1512553: Displacement of biotinylated probe from human TAF1 bromodomain 2 (1522 to 1656 residues) expressed in Escherichia coli BL21 (DE3) by alphascreen assay	ic50	0.0160	uM
6-but-3-enyl-4-[3-fluoro-5-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0170	uM
5-bromo-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0170	uM
ethyl N-[6-[3-(methanesulfonamido)-4-methylphenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate	1823230: Binding affinity to TAF1 BD 2 (unknown origin) assessed as dissociation constant	kd	0.0170	uM
6-(4-hydroxypiperidin-1-yl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0190	uM
1,3-dioxo-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-5-carbonitrile	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0220	uM
6-but-3-enyl-4-[3-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0230	uM
6-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0250	uM
4-[3-amino-5-(morpholine-4-carbonyl)phenyl]-6-but-3-enyl-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0260	uM
6-but-3-enyl-4-[6-(morpholine-4-carbonyl)-1H-benzimidazol-4-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0280	uM
4-[[(3R)-4-cyclopentyl-1,3-dimethyl-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-3-cyclopentyloxy-N-(1-methylpiperidin-4-yl)benzamide	1512553: Displacement of biotinylated probe from human TAF1 bromodomain 2 (1522 to 1656 residues) expressed in Escherichia coli BL21 (DE3) by alphascreen assay	ic50	0.0310	uM
8-[[1-(3-aminopropyl)piperidin-4-yl]amino]-5-[5-(hydroxymethyl)-3-pyridinyl]-3-methyl-1H-1,7-naphthyridin-2-one	1766137: Inhibition of TAF1 bromodomain 2 (unknown origin) by TR-FRET assay	ic50	0.0316	uM
5-amino-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482419: Inhibition of human GST-tagged TAF1 BD2 (1519 to 1651 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.0330	uM
6-but-3-enyl-4-[4-methyl-3-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0350	uM
6-but-3-enyl-4-[3-(pyrrolidine-1-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513930: Inhibition of recombinant His-tagged TAF1 bromodomain 2 (unknown origin) after 10 mins by TR-FRET assay	ic50	0.0350	uM
(3R)-6-[4-(4-hydroxypiperidine-1-carbonyl)-2-methoxyanilino]-1,3-dimethyl-4-(oxan-4-yl)-3H-pyrido[2,3-b]pyrazin-2-one	1512553: Displacement of biotinylated probe from human TAF1 bromodomain 2 (1522 to 1656 residues) expressed in Escherichia coli BL21 (DE3) by alphascreen assay	ic50	0.0380	uM

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, affects expression, affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
Ozone	affects cotreatment, decreases expression, increases abundance, affects expression	2
Valproic Acid	affects expression, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	increases expression	1
di-n-butylphosphoric acid	affects expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases expression, decreases reaction	1
epoxomicin	decreases expression, decreases reaction	1
CGP 52608	increases reaction, affects binding	1
2-palmitoylglycerol	increases expression	1
5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione	decreases expression, increases degradation, decreases reaction	1
Resveratrol	affects cotreatment, increases expression	1
Arsenic Trioxide	affects methylation	1
Troglitazone	decreases expression, increases degradation	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Cadmium	increases abundance, increases expression	1
Hydrogen Peroxide	affects expression	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	decreases expression	1
Thiram	increases expression	1
Paclitaxel	affects reaction, affects response to substance, decreases response to substance	1
Gold Compounds	decreases expression	1
Cadmium Chloride	increases abundance, increases expression	1
Volatile Organic Compounds	affects cotreatment, decreases expression	1

ChEMBL screening assays

140 unique, capped per target: 139 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3226588	Binding	Binding affinity to TAF1 bromodomain-2 (unknown origin) assessed as change in melting temperature at 10 uM by differential scanning fluorimetric analysis	The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. — Medchemcomm
CHEMBL5210064	Functional	Affinity Phenotypic Cellular interaction (AlamarBlue assay (cell viability in MOLM-13 cell line)) EUB0000191c TAF1	Affinity Phenotypic Cellular Literature for EUbOPEN Chemogenomics Library wave 3

Cellosaurus cell lines

9 cell lines: 9 finite cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SA42	ND50105	Finite cell line	Male
CVCL_SA44	ND50107	Finite cell line	Male
CVCL_UX27	NH50149	Finite cell line	Male
CVCL_UY46	NH50129	Finite cell line	Male
CVCL_UY53	NH50136	Finite cell line	Female
CVCL_YP40	NH50194	Finite cell line	Male
CVCL_YP77	NH50200	Finite cell line	Male
CVCL_YQ32	NH50241	Finite cell line	Male
CVCL_YQ42	NH50251	Finite cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder